 Athersys Inc NASDAQ: ATHX announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal, Intensive Care Medicine. MUST-ARDS Phase 12 trial evaluated the safety and efficacy of MultiStem invimestrocel cell therapy in patients with acute respiratory distress syndrome ARDS. 